Business Wire·Nov 9, 2026, 4:05 PM ET

AbCellera Reports Q3 2026 Business Results

AbCellera reported Q3 2026 financial results with total revenue of $10.6 million compared to $9.0 million in Q3 2025.
The company announced a net loss of $40.8 million for the quarter, a reduction from the $57.1 million loss in Q3 2025.
Positive top-line Phase 2 data for ABCL635 showed significant reductions in vasomotor symptoms, with late-stage development for menopausal VMS expected to begin in 2027.
AbCellera plans to expand ABCL635 indications to include hormone suppression-associated VMS in breast prostate cancer patients, with trials expected in 2027.
The company completed a $200 million capital offering of common shares pre-funded warrants, raising total available liquidity to approximately $890 million.
Three new pipeline programs were advanced to IND-enabling activities: ABCL992 (next-generation ABCL635 analog), ABCL385 (oncology), ABCL646 (ion channel antagonist).
Top-line Phase 1 data for ABCL575 met all endpoints for atopic dermatitis, but the company does not plan to develop the candidate past Phase 1.
Research Development expenses decreased to $43.5 million from $55.0 million in Q3 2025, while SG&A expenses dropped to $13.6 million from $25.0 million.
At the end of Q3 2026, AbCellera held downstream stakes in 12 progressing molecules, down from 44 programs led by partners at the end of 2025.
The company ended the quarter with over $790 million in cash balances marketable securities, supported by over $100 million in non-dilutive government funding.